Story Summary: It affects young children, almost exclusively boys, and leads to paralysis and death in young adulthood. DMD affects one in 3,500 males, making it the most prevalent of muscular dystrophies. AMT is developing a gene therapy product for DMD based on exon skipping technology which results in bypassing the genetic defect such that the functional protein can be formed again. Positive long-term therapeutic effects of this approach have been demonstrated in animals. Currently, AMT has a pipeline with nine products at different stages of research or development. Words such as strategy, expects, plans, anticipates, believes, will, continues, estimates, intends, projects, goals, targets and other words of similar meaning are intended to identify such forward-looking statements. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMTs business, including, but not limited to, the timely commencement and success of AMTs clinical trials and research endeavors, delays in receiving U. S. Food and Drug Administration or other regulatory approvals (i. e. EMEA, Health Canada), market acceptance of AMTs products, effectiveness of AMTs marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents….Read the Full Story

Related posts:

1. Trimeris Receives Request from Arigene for Extension of Tender Offer Period
2. NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
3. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
4. Preclinical Proof-of-Concept Studies Published For Novavax Seasonal Influenza Virus-Like-Particle Vaccine
5. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong